Page last updated: 2024-11-03

opc 12759 and Breast Cancer

opc 12759 has been researched along with Breast Cancer in 1 studies

rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase

Research Excerpts

ExcerptRelevanceReference
" We retrospectively examined the progression of oral mucositis in 91 patients with breast cancer who received the 5-fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 regimen between September 2007 and August 2008."3.80[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer]. ( Abe, M; Bamba, N; Enami, A; Makihara, K; Masaoka, M; Masuda, N; Mizutani, M; Shikata, A; Takada, S; Yamamoto, M; Yamamura, J; Yasojima, H, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Enami, A1
Masuda, N1
Yamamura, J1
Mizutani, M1
Yasojima, H1
Shikata, A1
Masaoka, M1
Takada, S1
Bamba, N1
Yamamoto, M1
Abe, M1
Makihara, K1

Other Studies

1 other study available for opc 12759 and Breast Cancer

ArticleYear
[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:11

    Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha

2014